Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Freund Creates Subsidiary in Europe
November 23, 2009
- Subcutaneous Velcade in PIII in US: Takeda
November 23, 2009
- Pfizer Starts Shipment of New Norvasc OD Tablets
November 16, 2009
- Olmetec Acquires 3rd-Largest Share in ARB Market in Japan
November 16, 2009
- Cut Prices of Off-Patent Original Drugs before Calling for Use of Generics: TMA
November 16, 2009
- DSP Hurries to Build Up Its Own Marketing System for Lurasidone
November 16, 2009
- Premium Prices Needed for Biosimilars: Mr Nagano at Chuikyo
November 16, 2009
- Kyorin Licenses Neramexane for Tinnitus from Merz
November 16, 2009
- Asahi Kasei Kuraray Medical's South Korean Subsidiary Starts Operation
November 16, 2009
- Banyu to Boost Its Vaccine Business with Pneumovax, Gardasil
November 16, 2009
- InCROM to Conduct Mock PI Trials for Drug Makers’Employees
November 16, 2009
- GSK to Promote Cervarix Targeting All Dept. and Deploying over 1,000 MRs
November 16, 2009
- Hospira Japan Launches GemStar PCA Pump
November 16, 2009
- Medipal to Further Drug Distribution System Reform
November 16, 2009
- Quintiles Is More Than a CRO: Dr Winstanly
November 16, 2009
- Alfresa to Begin Business in China in Earnest
November 16, 2009
- Eisai Reshuffles R&D System to Speed Up Development of Anticancer Drugs
November 16, 2009
- Big Changes in Style of Discussions at Chuikyo
November 16, 2009
- Strong Yen Hit Top-Eight Domestic Companies’Performance
November 16, 2009
- Pricing Rule to Be Revised for New Products Containing Existing API: Chuikyo
November 16, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…